Skip to content

Welcome to Discover Pharma! Today is : November 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

sustainability in pharma

  • Manufacturing & Supply Chain,Opinion & Events

    CPHI Milan to focus on practical sustainability across pharma supply chains

    CPHI Milan will bring pharmaceutical manufacturers, suppliers and sustainability leaders [...]

    October 3, 2026
  • Drug Discovery & Development,Manufacturing & Supply Chain,Opinion & Events,Pharmaceuticals and therapeutics

    CPhI & PMEC India 2025 showcases pharma innovation and sets stage for expanded 2026 edition

    The 18th edition of CPhI & PMEC India, South Asia’s [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Manufacturing & Supply Chain

    From clinical waste to carbon cuts: The firm helping pharma go green

    A Yorkshire-based company is quietly transforming how pharmaceutical and clinical [...]

    May 5, 2026
  • Manufacturing & Supply Chain

    Vetter named best managed company for sixth year

    Vetter, the Germany-based contract development and manufacturing organisation (CDMO), has [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • PsiThera raises $25m to advance oral TNFα and TL1A drugs
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • TaiMed reports 80% HIV viral suppression with dual-antibody regimen in Phase 2a study
    Categories: Clinical & Regulatory, Research & Development
  • PlaqueTec expands coronary artery disease trial to eight NHS centres
    Categories: Medical devices, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top